Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 28, 2025 07:00 ET | Source: Ampersand Biomedicines

Ampersand Biomedicines Presents Preclinical Data on AMP-410, a Novel Anti-VEGF/4-1BB Bifunctional AND-Body™ Therapeutic, at AACR 2025

Lead development candidate, AMP-410, leverages proprietary Ampersand technology to block VEGF and allosterically activate 4-1BB signaling – unlike traditional bispecific molecules – driving both...
March 19, 2025 07:00 ET | Source: Ampersand Biomedicines

Ampersand Biomedicines Raises Series B Financing and Highlights Pipeline Advancements

$65 million in Series B funding secured from investors, including founder Flagship Pioneering and Eli Lilly & Company Two lead programs in immuno-inflammation and immuno-oncology planned to enter...
February 11, 2025 08:00 ET | Source: Ampersand Biomedicines

Ampersand Biomedicines Appoints Elizabeth Mily to Board of Directors

Ampersand Biomedicines Appoints Elizabeth Mily to Board of Directors
January 03, 2024 06:30 ET | Source: Ampersand Biomedicines

Ampersand Biomedicines Acquires AbCheck to Accelerate Platform and Product Development

BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today...